In order to test whether DSC3 is epigenetically silenced by methylation in prostate cancer, we treated LNCaP cells with a DNA methylation inhibitor, 5-Aza-deoxycytidine (5-Aza). The gene discussed is DSC3; the disease is prostate carcinoma.